{
    "clinical_study": {
        "@rank": "126016", 
        "acronym": "VELDON", 
        "arm_group": {
            "arm_group_label": "Bortezomib", 
            "arm_group_type": "Experimental", 
            "description": "Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation"
        }, 
        "brief_summary": {
            "textblock": "The investigators plan to study the role of bortezomib for desensitizing patients awaiting a\n      living kidney donation who have a titer of Donor Specific anti human leucocyte antigen (HLA)\n      Antibody (DSA) between 1000 and 3000 MFI with a pilot study of 10 patients recruited in 4\n      hospital in FRANCE."
        }, 
        "brief_title": "Desensitization With Bortezomib Before a Living Kidney Donation", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Patients Awaiting a Living Kidney Donation", 
        "detailed_description": {
            "textblock": "The investigators plan to study the role of bortezomib for desensitizing patients awaiting a\n      living kidney donation who have a titer of Donor Specific anti HLA Antibody (DSA) between\n      1000 and 3000 MFI with a multicentre pilot study of 10 patients. The effect of bortezomib\n      will be observed up to 6 month after bortezomib treatment prior to transplantation and 12\n      month after transplantation if performed. The living kidney donation will be performed only\n      if the DSA level drops below 1000 MFI which means an efficacy of the desensitization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient between 18 and 70 years old\n\n          -  awaiting a living kidney donation\n\n          -  but with a least one DSA titer between 1000 MFI and 3000 MFI\n\n        Exclusion Criteria:\n\n          -  positive cell dependent cytotoxicity CM,\n\n          -  DSA level above 3000 MFI\n\n          -  and every condition  that is a contre indication for bortezomib treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01842074", 
            "org_study_id": "P110147", 
            "secondary_id": "2012-001988-78"
        }, 
        "intervention": {
            "arm_group_label": "Bortezomib", 
            "description": "Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation", 
            "intervention_name": "Bortezomib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Bortezomib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "bortezomib", 
            "desensitization", 
            "living kidney transplantation"
        ], 
        "lastchanged_date": "December 19, 2013", 
        "location": {
            "contact": {
                "email": "helene.francois@bct.aphp.fr", 
                "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
                "phone": "33(0)145212722"
            }, 
            "contact_backup": {
                "email": "antoine.durrbach@bct.aphp.fr", 
                "last_name": "Antoine Durrbach, MD, PhD", 
                "phone": "33(0)145212771"
            }, 
            "facility": {
                "address": {
                    "city": "Le KREMLIN-BICETRE", 
                    "country": "France", 
                    "zip": "94 275"
                }, 
                "name": "Assistance Publique - H\u00f4pitaux de Paris, Bic\u00eatre Hospital"
            }, 
            "investigator": {
                "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Desensitization With Bortezomib Before a Living Kidney Donation", 
        "overall_contact": {
            "email": "helene.francois@bct.aphp.fr", 
            "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
            "phone": "33(0)145212722"
        }, 
        "overall_contact_backup": {
            "email": "antoine.durrbach@bct.aphp.fr", 
            "last_name": "Antoine DURRBACH, MD, PhD", 
            "phone": "33(0)145212771"
        }, 
        "overall_official": {
            "affiliation": "Assistance Publique H\u00f4pitaux de Paris - Bic\u00eatre Hospital", 
            "last_name": "H\u00e9l\u00e8ne Fran\u00e7ois, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Bortezomib treatment should allow a decrease in DSA level below a threshold level authorizing the living kidney donation with minimal risk", 
            "measure": "Proportion of patients with Donor specific antibody (DSA) level below 1000MFI authorizing the living kidney donation", 
            "safety_issue": "Yes", 
            "time_frame": "up 6 months after bortezomib treatment and before transplantation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01842074"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection", 
                "measure": "Absolute and relative differences of the DSA titer ans antiHLA non DSA titer bortezomib treatment", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment", 
                "measure": "Frequency of clinical symptoms and anomalies", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment", 
                "measure": "Frequency of side effects", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment", 
                "measure": "Frequency of anomalies at the standard blood tests", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment", 
                "measure": "Frequency of anomalies at the total lymphocyte count and phenotyping", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment", 
                "measure": "Frequency of proteinuria and anomalies at the glomerular filtration rate", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection", 
                "measure": "Proportion of transplanted patients", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }, 
            {
                "description": "Safety and efficacy of bortezomib treatment 12 months after transplantation if performed, if not 6 month after the last bortezomib injection", 
                "measure": "Incidence of biopsy proven acute rejection and chronic rejection", 
                "safety_issue": "Yes", 
                "time_frame": "12 month after the living kidney donation if performed or 6 month after the last bortezomib injection if the living kidney donation could not be performed"
            }
        ], 
        "source": "Assistance Publique - H\u00f4pitaux de Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}